Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
Tim Diederichs(Boehringer Ingelheim (Germany)), Patrick Garidel(Boehringer Ingelheim (Germany)), James Harry Humphrey(Croda (United Kingdom)), Judith J. Mittag(Boehringer Ingelheim (Germany)), Stefan Carle(Boehringer Ingelheim (Germany)), Julia Buske(Boehringer Ingelheim (Germany)), Söhnke Voss(Croda (United Kingdom))
Cited by 14
Related Papers
Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates
|Pharmaceutics|2022|93
A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery
|International Journal of Pharmaceutics|2017|55
An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80
|International Journal of Pharmaceutics|2020|47
The Hsp90 machinery facilitates the transport of diphtheria toxin into human cells
|Scientific Reports|2017|42
Assessing the polysorbate degradation fingerprints and kinetics of lipases – how the activity of polysorbate degrading hydrolases is influenced by the assay and assay conditions
|European Journal of Pharmaceutical Sciences|2021|37